文献速递肝病

乙型肝炎治疗患者肝纤维化消退与肝脏相关事件减少相关

Regression of Liver Fibrosis in Patients on Hepatitis B Therapy Is Associated With Decreased Liver-Related Events.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-11-30

该研究纳入733例接受抗病毒治疗且治疗中肝活检显示显著纤维化或肝硬化的慢性乙型肝炎患者,按北京分类P-I-R评分评估纤维化消退。中位7年随访显示,消退组肝脏相关事件累积发生率低于进展组(4.1% vs 18.1%),调整后风险比为0.40(95%CI 0.16-0.99;P=.047)。

要点

  • P-I-R评分定义的纤维化消退与肝脏相关事件风险降低相关(调整HR 0.40)。
  • 7年肝脏相关事件累积发生率:消退组4.1%、不确定组8.7%、进展组18.1%。
  • 肝硬化或低血小板计数患者中亦观察到纤维化消退与肝脏相关事件减少的关联。

核心结论

  • 抗病毒治疗诱导的肝纤维化消退(经P-I-R评分评估)与肝脏相关事件减少相关,提示治疗中P-I-R评分评估的组织学纤维化消退可作为临床事件的替代终点。

研究设计与样本

  • 纳入733例接受治疗中肝活检且Ishak分期≥3的慢性乙型肝炎患者,根据北京分类P-I-R评分评估纤维化消退,采用Cox比例风险模型分析纤维化消退与肝脏相关事件的关联。

主要发现

  • 733例患者中Ishak 3/4期456例(62.2%),肝硬化(Ishak 5/6期)277例(37.8%)。
  • P-I-R评分显示纤维化消退314例(42.8%)、不确定230例(31.4%)、进展189例(25.8%)。
  • 7年肝脏相关事件累积发生率:消退组4.1%、不确定组8.7%、进展组18.1%(log-rank P<.001)。
  • 与纤维化进展组相比,消退组肝脏相关事件风险更低(调整HR 0.40;95%CI 0.16-0.99;P=.047),不确定组调整HR 0.86(95%CI 0.40-1.85;P=.691)。
  • 在肝硬化或血小板计数<150×10⁹/L患者中亦观察到纤维化消退与肝脏相关事件减少的关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Liver fibrosis in patients with chronic hepatitis B can regress with successful antiviral therapy. However, the long-term clinical benefits of fibrosis regression have not been fully elucidated. This study investigated the association between biopsy-proven fibrosis regression by predominantly progressive, indeterminate, and predominantly regressive (P-I-R) score and liver-related events (LREs) in chronic hepatitis B patients. METHODS: Patients with on-treatment liver biopsy and significant fibrosis/cirrhosis (Ishak stage ≥3) were included in this analysis. Fibrosis regression was evaluated according to the P-I-R score of the Beijing Classification. LREs were defined as decompensations, hepatocellular carcinoma, liver transplantation, or death. The Cox proportional hazards model was used to determine associations of fibrosis regression with LREs. RESULTS: A total of 733 patients with Ishak stages 3/4 (n = 456; 62.2%) and cirrhosis (Ishak stages 5/6; n = 277; 37.8%) by on-treatment liver biopsy were enrolled. According to the P-I-R score, fibrosis regression, indeterminate, and progression were observed in 314 (42.8%), 230 (31.4%), and 189 (25.8%) patients, respectively. The 7-year cumulative incidence of LREs was 4.1%, 8.7%, and 18.1% in regression, indeterminate, and progression, respectively (log-rank, P < .001). Compared with patients with fibrosis progression, those with fibrosis regression had a lower risk of LREs (adjusted hazard ratio, 0.40; 95% CI, 0.16-0.99; P = .047), followed by the indeterminate group (adjusted hazard ratio, 0.86; 95% CI, 0.40-1.85; P = .691). Notably, this favorable association also was observed in patients with cirrhosis or low platelet counts (<150 × 109/L). CONCLUSIONS: Antiviral therapy-induced liver fibrosis regression assessed by P-I-R score is associated with reduced LREs. This shows the utility of histologic fibrosis regression assessed by on-treatment P-I-R score as a surrogate endpoint for clinical events in patients with hepatitis B virus-related fibrosis or early cirrhosis.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Sun Y, Chen W, Chen S, et al. Regression of Liver Fibrosis in Patients on Hepatitis B Therapy Is Associated With Decreased Liver-Related Events. Clin Gastroenterol Hepatol. 2023. PMID: 38040276. doi:10.1016/j.cgh.2023.11.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。